Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Etanercept in erythema nodosum leprosum

2017; Elsevier BV; Volume: 92; Issue: 4 Linguagem: Inglês

10.1590/abd1806-4841.20175471

ISSN

1806-4841

Autores

Julia Rocha Silva Santos, Dâmia Leal Vendramini, José Augusto da Costa Nery, João Carlos Regazzi Avelleira,

Tópico(s)

Infectious Diseases and Tuberculosis

Resumo

One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.

Referência(s)